SAN FRANCISCO and BOSTON, May 11, 2026 /PRNewswire/ -- Benchling announced Benchling Biologics, an end-to-end platform for antibody R&D, today at the PEGS Boston Summit. Scientists can configure any ...
Investors are eager for the Benchling IPO. The company made headlines when it confidentially filed with the SEC to go public. Biotechnology is rewriting life as we know it. Our customers, spanning ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results